TIDMEKF
RNS Number : 9517Z
EKF Diagnostics Holdings PLC
26 May 2021
The following announcement from Trellus Health plc is being
linked to the EKF ticker for information purposes only
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM, THE UNITED STATES
OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA
OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS
ANNOUNCEMENT. THE READER'S ATTENTION IS DRAWN TO THE DISCLAIMER AT
THE END OF THIS ANNOUNCMENT.
Capitalised terms in this announcement have the same meanings as
in prior announcements
in relation to the Fundraising, unless otherwise indicated.
Trellus Health plc
("Trellus Health" or the "Company")
Successful Restricted Offer
Update on Fundraising and Admission
LONDON, UK. AND NEW YORK, U.S. (26 May 2021). Trellus Health plc
(AIM: TRLS), which is commercialising a resilience-based connected
digital health solution for chronic condition management, announces
the result of the Restricted Offer made to its shareholders, who
returned a valid application form to subscribe for Trellus Health
Ordinary Shares of GBP0.001 each ("Trellus Health Shares") at the
Issue Price, being 40 pence per share (the "Restricted Offer").
The Restricted Offer to raise up to GBP0.9 million in gross
proceeds was significantly oversubscribed.
The Placing, Subscription and Restricted Offer have, in
aggregate, raised GBP28.5 million through the issue of a total of
71,250,000 new Ordinary Shares at the Issue Price.
The allotment and issue of Trellus Health Shares in connection
with the Restricted Offer remains conditional upon, among other
things, Admission, which is expected to take place at 8:00 a.m. on
Friday, 28 May 2021.
Applicants to the Restricted Offer can confirm their final
allotment of shares by contacting the Link Group helpline on 0371
664 0321. Calls are charged at the standard geographic rate and
will vary by provider. Calls outside the United Kingdom will be
charged at the applicable international rate. The helpline is open
between 9.00 a.m. and 5.30 p.m., Monday to Friday excluding public
holidays in England and Wales. The helpline cannot provide any
financial, legal or tax advice and calls may be recorded and
monitored for security and training purposes.
Full details of the Fundraising will be contained in the Trellus
Health Admission Document, which will be made available shortly
before Admission at www.trellushealth.com/investors .
For further information please contact:
Trellus Health plc www.trellushealth.com.com
M onique Fayad , CEO Via Walbrook PR
Julian Baines, Chairman
As above
LINK Group (Receiving Agent)
N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000
Aubrey Powell / Jen Boorer / Hannah
Woodley
Walbrook PR Limited Tel: 020 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 077502 558 258
About Trellus Health plc (www.trellushealth.com)
Trellus Health is commercialising the provision of digital
chronic condition management solutions for employers and health
plans that utilise the scientifically validated GRITT(TM)
resilience-based methodology and a proprietary HIPAA-compliant
technology platform called TrellusElevate(TM) to coordinate and
deliver personalised care remotely via telemedicine. The Company is
initially focused on Inflammatory Bowel Diseases ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and
ulcerative colitis, but considers its approach to have potential
utility and demand across many chronic conditions.
The TrellusElevate(TM) platform is the Company's proprietary
connected health platform that incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. The GRITT(TM) methodology and resilience-driven
multidisciplinary care model have been scientifically validated to
demonstrate meaningful improvements in patient outcomes and over 85
per cent. reduction in unplanned healthcare utilisation (emergency
department visits and hospitalisations) which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers.
The Company was formed in July 2020 as a UK incorporated
company, with the exclusive license for commercialisation of the
GRITT(TM) methodology for IBD and seven broad disease categories
granted by the Icahn School of Medicine at Mount Sinai ("ISMMS").
On 20 August 2020, EKF Diagnostics Holdings plc ("EKF") announced
that it had led, in partnership with ISMMS, a $5 million strategic
investment into the Company. On 18 December 2020, EKF distributed
its investment in the Company to EKF shareholders on its register
at that time, by way of a dividend in specie of its entire holding
of 27,999,999 non-voting Trellus A Shares. Transfer of these shares
took place on 18 December 2020 to Broadway Nominees Limited to be
held on trust for the underlying EKF shareholders. On Admission,
all A Shares will convert to Ordinary Shares.
Disclaimer
This announcement is an advertisement for the purposes of the
Prospectus Regulation Rules of the UK Financial Conduct Authority
("FCA") and is not a prospectus nor an admission document. This
announcement is not and does not constitute, or form part of, and
should not be construed as, an offer or invitation to sell, allot
or issue or any solicitation of any offer to purchase or subscribe
for, any securities of the Company in any jurisdiction, nor shall
it (or any part of it) or the fact of its distribution form the
basis of, or be relied upon in connection with, or act as any
inducement to enter into, any contract or commitment for securities
in the Company in any jurisdiction, including in or into the United
States, Canada, Australia, the Republic of South Africa or Japan or
their respective territories or possessions. This announcement does
not constitute a recommendation regarding any securities.
Prospective investors should not subscribe for or purchase any
securities referred to in this announcement except in compliance
with applicable securities laws and regulation and on the basis of
the information in the Pathfinder, the P-Proof of the admission
document and the final admission document ("Admission Document") to
be published by the Company, and any supplement thereto, in
connection with the Fundraising and Admission. Following
publication, a copy of the Admission Document will be made
available on the Company's website. The information in this
announcement is for background purposes only and does not purport
to be full or complete.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZGZKVVDGMZM
(END) Dow Jones Newswires
May 26, 2021 12:48 ET (16:48 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2023 to Mar 2024